Steven P Treon

List of Publications by Year
in descending order

333 papers	19,630 citations	13332 70 h-index	14779 131 g-index
336 all docs	336 docs citations	336 times ranked	10036 citing authors

#	Article	IF	Citations
1	MYD88 L265P Somatic Mutation in WaldenstrÃ¶m's Macroglobulinemia. New England Journal of Medicine, 2012, 367, 826-833.	13.9	1,142
2	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 2001, 98, 210-216.	0.6	869
3	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 110-115.	0.8	841
4	Ibrutinib in Previously Treated WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440.	13.9	810
5	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	0.6	512
6	The genomic landscape of WaldenstrÃ¶m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 2014, 123, 1637-1646.	0.6	394
7	MYD88 L265P in WaldenstrÃ¶m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood, 2013, 121, 2051-2058.	0.6	368
8	International prognostic scoring system for WaldenstrÃ¶m macroglobulinemia. Blood, 2009, 113, 4163-4170.	0.6	366
9	Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in WaldenstrÃ¶m macroglobulinemia. Blood, 2014, 123, 2791-2796.	0.6	337
10	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chemical Biology, 2018, 25, 88-99.e6.	2.5	313
11	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in WaldenstrÃ¶m macroglobulinemia. Blood, 2013, 122, 1222-1232.	0.6	306
12	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology, 2005, 128, 192-203.	1.2	305
13	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 116-120.	0.8	304
14	Phase 3 Trial of Ibrutinib plus Rituximab in WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2018, 378, 2399-2410.	13.9	291
15	Primary Therapy of WaldenstrÃ¶m Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. Journal of Clinical Oncology, 2009, 27, 3830-3835.	0.8	265
16	Polymorphisms in FcÎ³RIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in WaldenstrÃ¶mâ€™s Macroglobulinemia. Journal of Clinical Oncology, 2005, 23, 474-481.	0.8	263
17	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19â€"infected patients. Blood, 2020, 135, 1912-1915.	0.6	253
18	Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcÎ³RIIIa-158 V/V and V/F polymorphism. Blood, 2007, 110, 2561-2564.	0.6	244

#	Article	IF	Citations
19	Response assessment in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia: update from the <scp>VI</scp>th <scp>I</scp>nternational <scp>W</scp>orkshop. British Journal of Haematology, 2013, 160, 171-176.	1.2	226
20	Diagnosis and Management of Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology, 2005, 23, 1564-1577.	0.8	225
21	<i>MYD88</i> Mutations and Response to Ibrutinib in WaldenstrÃ¶m's Macroglobulinemia. New England Journal of Medicine, 2015, 373, 584-586.	13.9	212
22	Ibrutinib for patients with rituximab-refractory WaldenstrÃ¶m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 241-250.	5.1	212
23	Update on Treatment Recommendations From the Fourth International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Journal of Clinical Oncology, 2009, 27, 120-126.	0.8	207
24	How I treat WaldenstrÃ¶m macroglobulinemia. Blood, 2009, 114, 2375-2385.	0.6	206
25	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. Journal of Immunotherapy, 2001, 24, 263-271.	1.2	188
26	Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. Clinical Cancer Research, 2007, 13, 3320-3325.	3.2	186
27	Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 1997, 15, 837-843.	2.6	177
28	Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With WaldenstrÃ¶m Macroglobulinemia Treated With Nucleoside Analogs. Journal of Clinical Oncology, 2009, 27, 250-255.	0.8	170
29	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating WaldenstrÃ¶m's macroglobulinemia. Blood, 2014, 124, 503-510.	0.6	168
30	How I treat WaldenstrÃ¶m macroglobulinemia. Blood, 2015, 126, 721-732.	0.6	165
31	Treatment recommendations from the Eighth International Workshop on WaldenstrÃ¶mâ€™s Macroglobulinemia. Blood, 2016, 128, 1321-1328.	0.6	161
32	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1422-1428.	0.8	150
33	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstromâ€™s Macroglobulinemia. Journal of Immunotherapy, 2001, 24, 272-279.	1.2	144
34	Ibrutinib Monotherapy in Symptomatic, Treatment-NaÃ¯ve Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2018, 36, 2755-2761.	0.8	142
35	The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 2007, 110, 4417-4426.	0.6	141
36	Long-term outcomes to fludarabine and rituximab in WaldenstrÃ¶m macroglobulinemia. Blood, 2009, 113, 3673-3678.	0.6	141

#	Article	IF	Citations
37	Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2010, 85, 670-674.	2.0	138
38	Treatment recommendations for patients with WaldenstrÃ¶m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	0.6	138
39	Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood, 2008, 112, 4452-4457.	0.6	135
40	Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H). Clinical Cancer Research, 2006, 12, 7174-7179.	3.2	133
41	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1408-1414.	0.8	132
42	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Research, 2004, 64, 2846-2852.	0.4	126
43	Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2009, 15, 355-360.	3.2	124
44	CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications. Journal of Immunotherapy, 2002, 25, 72-81.	1.2	123
45	Clonal architecture of <i><scp>CXCR</scp>4 </i><scp>WHIM</scp>â€like mutations in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 172, 735-744.	1.2	122
46	Acquired mutations associated with ibrutinib resistance in WaldenstrÃ¶m macroglobulinemia. Blood, 2017, 129, 2519-2525.	0.6	115
47	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica, 2017, 102, 43-51.	1.7	112
48	Overall survival and competing risks of death in patients withÂ<scp>W</scp>aldenstrÃ¶m macroglobulinaemia: an analysis of the <scp>S</scp>urveillance, <scp>E</scp>pidemiology and <scp>E</scp>nd <scp>R</scp>esults database. British Journal of Haematology, 2015, 169, 81-89.	1.2	110
49	Update on Recommendations for Assessing Response from the Third International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2006, 6, 380-383.	1.4	107
50	Targeting NF-ÎºB in Waldenstrom macroglobulinemia. Blood, 2008, 111, 5068-5077.	0.6	106
51	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	0.8	103
52	Bendamustine Therapy in Patients With Relapsed or Refractory WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 133-135.	0.2	101
53	Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in WaldenstrÃ¶m macroglobulinemia. Blood, 2007, 109, 4964-4972.	0.6	100
54	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	0.8	98

#	Article	IF	Citations
55	Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	2.2	96
56	<i><scp>CXCR</scp>4 </i><scp>WHIM</scp>â€like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant <i><scp>MYD</scp>88</i>^{L265P}â€directed survival signalling in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia cells. British Journal of Haematology, 2015, 168, 701-707.	1.2	95
57	Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 121-126.	0.8	94
58	Hyperviscosity-Related Retinopathy in WaldenstrÃ¶m Macroglobulinemia. JAMA Ophthalmology, 2006, 124, 1601.	2.6	94
59	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood, 2016, 127, 3237-3252.	0.6	93
60	Maintenance Rituximab is associated with improved clinical outcome in rituximab naÃ¯ve patients with Waldenstrom Macroglobulinaemia who respond to a rituximabâ€containing regimen. British Journal of Haematology, 2011, 154, 357-362.	1.2	92
61	Survival trends in WaldenstrÃ¶m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood, 2014, 123, 3999-4000.	0.6	91
62	Transcriptome sequencing reveals a profile that corresponds to genomic variants in WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 128, 827-838.	0.6	91
63	Central nervous system involvement by WaldenstrÃ¶m macroglobulinaemia (Bingâ€Neel syndrome): a multiâ€institutional retrospective study. British Journal of Haematology, 2016, 172, 709-715.	1.2	87
64	Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 127-131.	0.8	86
65	<i><scp>MYD</scp>88</i> wildâ€type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andÂoverall survival. British Journal of Haematology, 2018, 180, 374-380.	1.2	83
66	Dual targeting of the proteasome regulates survival and homing in WaldenstrÃ¶m macroglobulinemia. Blood, 2008, 111, 4752-4763.	0.6	79
67	The Cyclophilin Aâ€“CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nature Medicine, 2015, 21, 572-580.	15.2	79
68	Genomics, Signaling, and Treatment of WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2017, 35, 994-1001.	0.8	76
69	Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenstroÿm's Macroglobulinemia. Clinical Cancer Research, 2008, 14, 1849-1858.	3.2	75
70	CD27-CD70 interactions in the pathogenesis of WaldenstrÃ¶m macroglobulinemia. Blood, 2008, 112, 4683-4689.	0.6	74
71	<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with WaldenstrÃ¶m macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 2019, 187, 356-363.	1.2	73
72	Insights into the genomic landscape of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2018, 2, 2937-2946.	2.5	72

#	Article	IF	Citations
73	CD5, CD10, and CD23 Expression in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 246-249.	2.1	71
74	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. British Journal of Haematology, 2019, 184, 558-569.	1.2	71
75	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood, 2019, 133, 299-305.	0.6	69
76	Longâ€term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American Journal of Hematology, 2014, 89, 237-242.	2.0	68
77	Renal disease related to WaldenstrÃ¶m macroglobulinaemia: incidence, pathology and clinical outcomes. British Journal of Haematology, 2016, 175, 623-630.	1.2	68
78	Progression Risk Stratification of Asymptomatic WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2019, 37, 1403-1411.	0.8	65
79	Hepatitis C viral infection is not associated with WaldenstrÃ¶m's macroglobulinemia. American Journal of Hematology, 2007, 82, 83-84.	2.0	64
80	Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 62-66.	1.4	63
81	The <scp>BCL</scp>2 antagonist <scp>ABT</scp>â€199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in <i><scp>CXCR</scp>4</i>^{<i>Wildâ€type</i>} and <i><scp>CXCR</scp>4</i><scp>^{<i>WHIM</i>}</scp> mutated Waldenstrom macroglobulinaemia cells. British Journal of Haematology, 2015, 170, 134-138.	1.2	63
82	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for WaldenstrÃ¶m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology, 2022, 40, 52-62.	0.8	62
83	Establishment of BCWM.1 cell line for WaldenstrÃ¶m's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Experimental Hematology, 2007, 35, 1366-1375.	0.2	61
84	Attainment of complete/very good partial response following rituximabâ€based therapy is an important determinant to progressionâ€free survival, and is impacted by polymorphisms in <i>FCGR3A</i> in Waldenstrom macroglobulinaemia. British Journal of Haematology, 2011, 154, 223-228.	1.2	61
85	Recommendations for the diagnosis and initial evaluation of patients with WaldenstrÃ¶m Macroglobulinaemia: A Task Force from the 8th International Workshop on WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	1.2	61
86	BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood, 2018, 131, 2047-2059.	0.6	61
87	Ibrutinib discontinuation in WaldenstrÃ¶m macroglobulinemia: Etiologies, outcomes, and IgM rebound. American Journal of Hematology, 2018, 93, 511-517.	2.0	61
88	Investigation and management of IgM and WaldenstrÃ¶mâ€associated peripheral neuropathies: recommendations from the <scp>IWWM</scp>â€8 consensus panel. British Journal of Haematology, 2017, 176, 728-742.	1.2	58
89	Serum IgM level as predictor of symptomatic hyperviscosity in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 177, 717-725.	1.2	58
90	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2018, 24, 3247-3252.	3.2	57

#	Article	IF	Citations
91	Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. British Journal of Haematology, 2017, 179, 339-341.	1.2	56
92	CHOP plus Rituximab Therapy in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 273-277.	2.1	55
93	IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia. Haematologica, 2010, 95, 470-475.	1.7	53
94	Histological transformation to diffuse large Bâ€cell lymphoma in patients with WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2016, 91, 1032-1035.	2.0	53
95	CXCR4 in WaldenstrÃ¶mâ€™s Macroglobulinema: chances and challenges. Leukemia, 2021, 35, 333-345.	3.3	53
96	Venetoclax in Previously Treated WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2022, 40, 63-71.	0.8	53
97	Atrial fibrillation associated with ibrutinib in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2016, 91, E312-3.	2.0	52
98	A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood, 2013, 121, 4434-4436.	0.6	50
99	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, 2022, 36, 532-539.	3.3	50
100	Extramedullary WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2015, 90, 100-104.	2.0	47
101	Novel biologically based therapies for Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 309-312.	0.8	45
102	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. British Journal of Haematology, 2003, 121, 592-596.	1.2	45
103	Ibrutinib withdrawal symptoms in patients with WaldenstrÃ¶m macroglobulinemia. Haematologica, 2018, 103, e307-e310.	1.7	45
104	How we manage Bingâ€"Neel syndrome. British Journal of Haematology, 2019, 187, 277-285.	1.2	45
105	Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2008, 49, 1104-1107.	0.6	44
106	Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood, 2011, 118, 276-281.	0.6	42
107	CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in WaldenstrÃ¶m's Macroglobulinemia and Mast Cell Disorders. Clinical Lymphoma and Myeloma, 2006, 6, 478-483.	1.4	41
108	Response and survival for primary therapy combination regimens and maintenance rituximab in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 181, 77-85.	1.2	41

#	Article	IF	Citations
109	Balancing Risk Versus Benefit in the Treatment of WaldenstrÃ¶m's Macroglobulinemia Patients with Nucleoside Analogueâ€"Based Therapy. Clinical Lymphoma and Myeloma, 2009, 9, 71-73.	1.4	40
110	WaldenstrÃ¶mâ€™s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1211-1219.	2.3	38
111	Evolution of Management and Outcomes in WaldenstrÃ¶m Macroglobulinemia: A Population-Based Analysis. Oncologist, 2016, 21, 1377-1386.	1.9	36
112	Extracellular vesicleâ€"mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. Blood, 2018, 131, 1720-1729.	0.6	36
113	Associated Malignancies in Patients with WaldenstrÃ¶m's Macroglobulinemia and Their Kin. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 88-92.	0.2	35
114	Ixazomib, dexamethasone, and rituximab in treatment-naive patients with WaldenstrÃ¶m macroglobulinemia: long-term follow-up. Blood Advances, 2020, 4, 3952-3959.	2.5	35
115	Rituximab intolerance in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2016, 174, 645-648.	1.2	34
116	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal, 2020, 10, 12.	2.8	34
117	Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. Seminars in Oncology, 2003, 30, 248-252.	0.8	33
118	Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 160-163.	0.2	33
119	Incidence of secondary malignancies among patients with <scp>W</scp>aldenstrÃ¶m macroglobulinemia: An analysis of the <scp>SEER</scp> database. Cancer, 2015, 121, 2230-2236.	2.0	33
120	<i><scp>TP</scp>53</i> mutations are associated with mutated <i><scp>MYD</scp>88</i> and <i><scp>CXCR</scp>4</i>, and confer an adverse outcome in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2019, 184, 242-245.	1.2	33
121	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated WaldenstrÃ¶m macroglobulinemia. Blood, 2021, 138, 1535-1539.	0.6	32
122	Idelalisib in WaldenstrÃ¶m macroglobulinemia: high incidence of hepatotoxicity. Leukemia and Lymphoma, 2017, 58, 1002-1004.	0.6	31
123	Genetic Linkage of FcgÎ³RIIa and FcÎ³RIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy. Clinical Lymphoma and Myeloma, 2007, 7, 286-290.	1.4	30
124	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. Haematologica, 2016, 101, e111-e115.	1.7	30
125	<i>MYD88</i> mutated and wild-type WaldenstrÃ¶mâ€™s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in <i>CXCR4</i>. Haematologica, 2018, 103, e408-e411.	1.7	30
126	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 2018, 132, 2608-2612.	0.6	29

#	Article	IF	Citations
127	CXCR4 mutations affect presentation and outcomes in patients with WaldenstrÃ¶m macroglobulinemia: A systematic review. Expert Review of Hematology, 2019, 12, 873-881.	1.0	29
128	Ophthalmologic Techniques to Assess the Severity of Hyperviscosity Syndrome and the Effect of Plasmapheresis in Patients with WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 100-103.	1.4	28
129	Ibrutinib in WaldenstrÃ¶m macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 2016, 7, 179-186.	1.1	28
130	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with WaldenstrÃ¶m Macroglobulinemia (WM). Blood, 2014, 124, 1715-1715.	0.6	28
131	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2019, 3, 2800-2803.	2.5	27
132	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood, 2021, 138, 2002-2005.	0.6	27
133	Clinical Responses to Sildenafil in Waldenstrom's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2004, 5, 205-207.	2.1	26
134	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clinical Cancer Research, 2016, 22, 2226-2236.	3.2	26
135	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer Journal (Sudbury, Mass), 2016, 22, 34-39.	1.0	25
136	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Advances, 2019, 3, 3360-3374.	2.5	25
137	Familial Disease Predisposition Impacts Treatment Outcome in Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 433-437.	0.2	24
138	Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2019, 25, 369-377.	3.2	24
139	Management of WaldenstrÃ¶m macroglobulinemia in 2020. Hematology American Society of Hematology Education Program, 2020, 2020, 372-379.	0.9	24
140	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. OncoImmunology, 2017, 6, e1321184.	2.1	23
141	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clinical Cancer Research, 2017, 23, 2400-2404.	3.2	23
142	Genomic evolution of ibrutinibâ€resistant clones in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2020, 189, 1165-1170.	1.2	23
143	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 1833-1833.	0.6	23
144	Report of the Third International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 215-216.	2.1	22

#	Article	IF	Citations
145	Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 152-156.	0.2	22
146	Exome sequencing reveals recurrent germ line variants in patients with familial WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 127, 2598-2606.	0.6	22
147	CXCL13 levels are elevated in patients with WaldenstrÃ¶m macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica, 2017, 102, e452-e455.	1.7	22
148	To select or not to select? The role of Bâ€cell selection in determining the <i><scp>MYD</scp>88</i> mutation status in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2017, 176, 822-824.	1.2	22
149	Involvement of Ets Factor Spi-B and Id2 In WaldenstroÌˆm's Macroglobulinemia. Blood, 2010, 116, 129-129.	0.6	22
150	Defining Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 107-109.	0.8	21
151	The HMGâ€CoA inhibitor, simvastatin, triggers <i>in vitro</i> antiâ€tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. British Journal of Haematology, 2008, 142, 775-785.	1.2	21
152	WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2014, 28, 945-970.	0.9	21
153	Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood, 2009, 113, 626-634.	0.6	20
154	Bortezomib as a Treatment Option in Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 110-117.	0.2	20
155	Single-Agent Ibrutinib for Rituximab-Refractory WaldenstrÃ¶m Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clinical Cancer Research, 2021, 27, 5793-5800.	3.2	20
156	Ibrutinib Treatment in WaldenstrÃ¶m's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study. Blood, 2018, 132, 149-149.	0.6	20
157	Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 56-58.	1.4	19
158	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2015, 21, 2538-2545.	3.2	19
159	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of WaldenstrÃ¶m Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clinical Cancer Research, 2016, 22, 6099-6109.	3.2	19
160	<i><scp>MYD</scp>88</i> mutations can be used to identify malignant pleural effusions in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 180, 578-581.	1.2	19
161	What is new in the treatment of Waldenstrom macroglobulinemia?. Leukemia, 2019, 33, 2555-2562.	3.3	19
162	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2019, 184, 1011-1014.	1.2	19

#	ARTICLE	IF	CITATIONS
163	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. Blood, 2020, 136, 24-26.	0.6	19
164	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 1516-1516.	0.6	19
165	Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. British Journal of Haematology, 2009, 145, 59-63.	1.2	17
166	Patients With WaldenstrÃ¶m Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 241-243.	0.2	17
167	Biology, Prognosis, and Therapy of WaldenstrÃ¶m Macroglobulinemia. Cancer Treatment and Research, 2015, 165, 177-195.	0.2	17
168	Profiling of circulating exosomal miRNAs in patients with WaldenstrÃ¶m Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	1.1	17
169	Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 2951-2951.	0.6	17
170	Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor<i>SPIB</i>in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2014, 166, 677-689.	1.2	16
171	MYD88-independent growth and survival effects of Sp1 transactivation in WaldenstrÃ¶m macroglobulinemia. Blood, 2014, 123, 2673-2681.	0.6	16
172	WaldenstrÃ¶m macroglobulinemia: from biology to treatment. Expert Review of Hematology, 2014, 7, 157-168.	1.0	16
173	Initial Evaluation of the Patient with WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 811-820.	0.9	16
174	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 745-752.	0.9	16
175	Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic nextâ€generation sequencing in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 194, 730-733.	1.2	16
176	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 2021, 138, 1966-1979.	0.6	16
177	Novel Agents in the Treatment of WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2007, 7, S199-S206.	1.4	15
178	Targeting Myddosome Signaling in WaldenstrÃ¶m's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clinical Cancer Research, 2018, 24, 6408-6420.	3.2	15
179	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in WaldenstrÃ¶m Macroglobulinemia. HemaSphere, 2021, 5, e624.	1.2	15
180	Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 300-300.	0.6	15

#	Article	IF	Citations
181	Bendamustine-Based Therapy Is Highly Active In Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. Blood, 2010, 116, 4700-4700.	0.6	15
182	microRNA Aberrations in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 205-207.	0.2	14
183	Comparative outcomes of immunochemotherapy regimens in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 179, 106-115.	1.2	14
184	Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: A preliminary study. Cancer Epidemiology, 2012, 36, 294-297.	0.8	13
185	XIII. WaldenstrÃ¶m's macroglobulinaemia: an indolent Bâ€cell lymphoma with distinct molecular and clinical features. Hematological Oncology, 2013, 31, 76-80.	0.8	13
186	Proteasome inhibitors in WaldenstrÃ¶m macroglobulinemia. Blood, 2013, 122, 3243-3244.	0.6	13
187	Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. American Journal of Hematology, 2015, 90, E122-3.	2.0	13
188	Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. British Journal of Haematology, 2017, 177, 808-813.	1.2	13
189	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Advances, 2020, 4, 141-153.	2.5	13
190	B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstromâ€™s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.. Blood, 2004, 104, 3358-3358.	0.6	13
191	Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with WaldenstrÃ¶m macroglobulinaemia on ibrutinib. British Journal of Haematology, 2019, 185, 788-790.	1.2	12
192	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With WaldenstrÃ¶m Macroglobulinemia on and off Clinical Trials. HemaSphere, 2020, 4, e363.	1.2	12
193	<scp>CXCR4</scp> mutational status does not impact outcomes in patients with <scp>W</scp>aldenstrÃ¶m macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 2020, 95, E95-E98.	2.0	12
194	Response and survival predictors in a cohort of 319 patients with WaldenstrÃ¶m macroglobulinemia treated with ibrutinib monotherapy. Blood Advances, 2022, 6, 1015-1024.	2.5	12
195	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Journal of Immunotherapy (1993-1997), 2001, 24, 272-279.	0.1	12
196	Advances in the Biology and Treatment of WaldenstrÃ¶m's Macroglobulinemia: A Report from the 5th International Workshop on WaldenstrÃ¶m's Macroglobulinemia, Stockholm, Sweden. Clinical Lymphoma and Myeloma, 2009, 9, 10-15.	1.4	11
197	Consensus Statement on the Management of WaldenstrÃ¶m Macroglobulinemia Patients During the COVIDâ€19Pandemic. HemaSphere, 2020, 4, e433.	1.2	11
198	Natural history of WaldenstrÃ¶m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	1.7	11

#	Article	IF	Citations
199	Serum Free Light Chain in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2420-2420.	0.6	11
200	Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 4004-4004.	0.6	11
201	A prognostic index predicting survival in transformed WaldenstrÃ¶m macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	1.7	11
202	Interleukin-17 and TH17 Pathway Supports Waldenstrom's Macroglobulinemia Cell-Growth: Potential Therapeutic Implications. Blood, 2010, 116, 446-446.	0.6	11
203	IgM-MM is predominantly a preâ€“germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood, 2021, 138, 1980-1985.	0.6	11
204	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. Journal of Immunotherapy (1993-1997), 2001, 24, 263-271.	0.1	11
205	Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstromâ€™s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.. Blood, 2006, 108, 2765-2765.	0.6	10
206	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2022, 6, 2230-2235.	2.5	10
207	Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in WaldenstrÃ¶m macroglobulinemia cells. Leukemia and Lymphoma, 2011, 52, 1777-1786.	0.6	9
208	Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 250-252.	0.2	9
209	Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e39-e40.	0.2	9
210	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394.	0.6	9
211	Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2886-2886.	0.6	9
212	A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88. Blood, 2018, 132, 40-40.	0.6	9
213	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. Blood, 2010, 116, 3952-3952.	0.6	9
214	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for WaldenstrÃ¶m macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	0.8	9
215	Partial response or better at sixÂmonths is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	1.2	8
216	Cellâ€free <scp>DNA</scp> analysis for detection of <scp><i>MYD88</i>^{L265P}</scp> and <scp><i>CXCR4</i>^{S338X}</scp> mutations in <scp>W</scp>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253.	2.0	8

#	Article	IF	Citations
217	Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstromâ€™s Macroglobulinemia by Gene Expression Profiling.. Blood, 2007, 110, 3174-3174.	0.6	8
218	A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas. Blood, 2011, 118, 261-261.	0.6	8
219	Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. Blood, 2016, 128, 2984-2984.	0.6	8
220	Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with WaldenstrÃ¶m's Macroglobulinemia with <i>MYD88</i> and <i>CXCR4</i> Mutations. Blood, 2021, 138, 1362-1362.	0.6	8
221	Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 126-132.	1.4	7
222	Toward personalized treatment in WaldenstrÃ¶m macroglobulinemia. Hematology American Society of Hematology Education Program, 2017, 2017, 365-370.	0.9	7
223	The race to stymie BTK: zanu zings. Blood, 2020, 136, 1997-1999.	0.6	7
224	Epigenetic targeting of WaldenstrÃ¶m macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics, 2021, 13, 129-144.	1.0	7
225	Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory WaldenstrÃ¶m's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial. Blood, 2020, 136, 38-39.	0.6	7
226	Phase II Study of CC-5013 (Revlimid) and Rituximab in WaldenstroÌˆmâ€™s Macroglobulinemia: Preliminary Safety and Efficacy Results.. Blood, 2005, 106, 2443-2443.	0.6	7
227	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. Blood, 2008, 112, 832-832.	0.6	7
228	FcÎ³ Receptor Predictive Genomic Testing and the Treatment of Indolent Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 321-322.	0.2	6
229	Novel approaches to targeting MYD88 in WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2017, 10, 739-744.	1.0	6
230	Deepening of response after completing rituximabâ€containing therapy in patients with Waldenstrom macroglobulinemia. American Journal of Hematology, 2020, 95, 372-378.	2.0	6
231	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 547-556.	0.2	6
232	Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. Open Forum Infectious Diseases, 2022, 9, ofac104.	0.4	6
233	Epigenomics in WaldenstrÃ¶m macroglobulinemia. Blood, 2020, 136, 527-529.	0.6	5
234	How to Sequence Therapies in WaldenstrÃ¶m Macroglobulinemia. Current Treatment Options in Oncology, 2021, 22, 92.	1.3	5

#	Article	IF	Citations
235	Establishment of a Waldenstromâ€™s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. Blood, 2005, 106, 979-979.	0.6	5
236	IgA and IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstromâ€™s Macroglobulinemia Patients and May Be Related to Mutations Associated with Common Variable Immunodeficiency Disorder (CVID). Blood, 2008, 112, 3749-3749.	0.6	5
237	Whole-Genome Sequencing Results From 30 Patients with Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 434-434.	0.6	5
238	What should be the goal of therapy for WaldenstrÃ¶m macroglobulinemia patients? Complete response should be the goal of therapy. Blood Advances, 2017, 1, 2486-2490.	2.5	5
239	Future therapeutic options for patients with WaldenstrÃ¶m macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 206-215.	0.7	4
240	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leukemia and Lymphoma, 2016, 57, 2699-2701.	0.6	4
241	Long survival in patients with WaldenstrÃ¶m macroglobulinaemia diagnosed at a young age. British Journal of Haematology, 2019, 185, 799-802.	1.2	4
242	Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia. Blood, 2018, 132, 1566-1566.	0.6	4
243	Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstroˆmâ€™s Macroglobulinemia (WM).. Blood, 2006, 108, 2490-2490.	0.6	4
244	The Rituximab and IVIG Related IgM Flare In Waldenstrom's Macroglobulinemia Is Associated with Monocytic Activation of Fcgriia Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways. Blood, 2010, 116, 2870-2870.	0.6	4
245	The importance of the genomic landscape in WaldenstrÃ¶m's Macroglobulinemia for targeted therapeutical interventions. Oncotarget, 2017, 8, 35435-35444.	0.8	4
246	High frequency of central nervous system involvement in transformed WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	2.5	4
247	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances, 2022, 6, 3332-3338.	2.5	4
248	Waldenstrom's Macrogloblinemia/ Lymphoplasmacytic Lymphoma. , 2008, 142, 211-242.		4
249	Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics: Targets and Therapy, 2008, 2, 419.	3.0	3
250	Comparative genomics of CXCR4MUT and CXCR4WT single cells in WaldenstrÃ¶mâ€™s macroglobulinemia. Blood Advances, 2020, 4, 4550-4553.	2.5	3
251	Clinical application of genomics in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 1805-1815.	0.6	3
252	Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstromâ€™s Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.. Blood, 2005, 106, 980-980.	0.6	3

#	Article	IF	Citations
253	Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstromâ€™s Macroglobulinemia.. Blood, 2006, 108, 2517-2517.	0.6	3
254	Treatment with a Bortezomib-Containing Regimen Is Associated with Better Therapeutic Outcomes in Patients with Waldenstrom's Macroglobulinemia Who Have Familial Disease Predisposition. Blood, 2011, 118, 1643-1643.	0.6	3
255	Incidence of Peripheral Neuropathy in WaldenstroÌˆm Macroglobulinemia Patients At Diagnosis,. Blood, 2011, 118, 3692-3692.	0.6	3
256	Polymorphisms in FcÎ³RIIIA Are Genetically Linked to FcÎ³RIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in FcÎ³RIIIA-158 in Determining Rituximab Responses.. Blood, 2005, 106, 2433-2433.	0.6	3
257	Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1. Frontiers in Immunology, 2021, 12, 790258.	2.2	3
258	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Review of Anticancer Therapy, 2022, , .	1.1	3
259	WaldenstrÃ¶mâ€™s Macroglobulinemia. Hematologic Malignancies, 2018, , 191-220.	0.2	2
260	The real world of WaldenstrÃ¶m's macroglobulinaemia. Lancet Haematology,the, 2018, 5, e275-e276.	2.2	2
261	Reducing treatment toxicity in WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Drug Safety, 2021, 20, 1-8.	1.0	2
262	Plasmablastic lymphoma transformation in a patient with WaldenstrÃ¶m macroglobulinemia treated with ibrutinib. British Journal of Haematology, 2021, 195, 466-468.	1.2	2
263	Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 4929-4929.	0.6	2
264	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstromâ€™s Macroglobulinemia.. Blood, 2006, 108, 2496-2496.	0.6	2
265	Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstromâ€™s Macroglobulinemia (WM).. Blood, 2006, 108, 4749-4749.	0.6	2
266	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4496-4496.	0.6	2
267	Microrna Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy. Blood, 2008, 112, 96-96.	0.6	2
268	Imatinib Mesylate (GleevecÂ®) Is Active in Relapsed/Refractory Waldenstromâ€™s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.. Blood, 2006, 108, 2484-2484.	0.6	2
269	The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2418-2418.	0.6	2
270	Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2488-2488.	0.6	2

#	Article	IF	Citations
271	Role of CCL5 and Interleukin-6 in the Biology of WaldenstroÌˆm Macroglobulinemia.. Blood, 2007, 110, 688-688.	0.6	2
272	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstromâ€™s Macroglobulinemia.. Blood, 2007, 110, 1383-1383.	0.6	2
273	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and WaldenstroÌˆm's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. Blood, 2010, 116, 2988-2988.	0.6	2
274	Aberrant Expression of Regulatory miRNAs and Transcripts for IRS-PI3K Growth and Survival Signaling In Waldenstrom's Macroglobulinemia. Blood, 2010, 116, 1912-1912.	0.6	2
275	Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile. Blood, 2010, 116, 2010-2010.	0.6	2
276	Epigenomics in Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 156-160.	0.7	1
277	Treatment Recommendations in WaldenstrÃ¶m Macroglobulinemia. , 2017, , 367-370.		1
278	Genetic and Signaling Abnormalities in Waldenstromâ€™s Macroglobulinemia. , 2017, , 53-65.		1
279	Comparing apples to oranges: A commentary on the <scp>M</scp>ayo study of <scp>MYD</scp>88 significance in <scp>W</scp>aldenstrom's macroglobulinemia.. American Journal of Hematology, 2018, 93, E69-E71.	2.0	1
280	Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, E201.	2.0	1
281	Genomic landscape of WaldenstrÃ¶m's macroglobulinemia. HemaSphere, 2019, 3, 58-61.	1.2	1
282	Clinical Responses to Sildenafil in Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 4926-4926.	0.6	1
283	CHOP Plus Rituximab (CHOP-R) in WaldenstroÌˆmâ€™s Macroglobulinemia (WM).. Blood, 2004, 104, 4930-4930.	0.6	1
284	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. Blood, 2005, 106, 3398-3398.	0.6	1
285	Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 1486-1486.	0.6	1
286	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory WaldenstroÌˆm Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4493-4493.	0.6	1
287	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood, 2008, 112, 1011-1011.	0.6	1
288	Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 3750-3750.	0.6	1

#	Article	IF	Citations
289	Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab.. Blood, 2009, 114, 3930-3930.	0.6	1
290	The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM). Blood, 2010, 116, 4904-4904.	0.6	1
291	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 2705-2705.	0.6	1
292	Polymorphisms in the Hyaluronan Synthase 1 Gene May Be Predisposing Factors for Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 1363-1363.	0.6	1
293	Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies.. Blood, 2005, 106, 3346-3346.	0.6	1
294	Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstromâ€™s Macroglobulinemia (WM).. Blood, 2005, 106, 991-991.	0.6	1
295	Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstromâ€™s Macroglobulinemia, the Role of the ERK and PKC Pathways.. Blood, 2006, 108, 2416-2416.	0.6	1
296	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4494-4494.	0.6	1
297	Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance. Blood, 2010, 116, 1911-1911.	0.6	1
298	Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF-Î°Î² and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 597-597.	0.6	1
299	Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and WaldenstroÌˆm Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment. Blood, 2011, 118, 883-883.	0.6	1
300	MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase. Blood, 2012, 120, 897-897.	0.6	1
301	A pilot study on dasatinib in patients with WaldenstrÃ¶m macroglobulinemia progressing on ibrutinib. EJHaem, 2022, 3, 927-929.	0.4	1
302	WALDENSTRÃ–M MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA. , 0, , 129-149.		0
303	Waldenstromâ€™s macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 190-215.		0
304	WaldenstrÃ¶m's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 138-154.		0
305	12. WaldenstrÃ¶mâ€™s macroglobulinemia. , 2016, , 229-244.		0
306	Signal Inhibitors in Waldenstromâ€™s Macroglobulinemia. , 2017, , 327-334.		0

#	Article	IF	Citations
307	Immunomodulatory Agents and Proteasome Inhibitors in Waldenstromâ€™s Macroglobulinemia. , 2017, , 335-343.		0
308	Fitting mSMART Into the Current Clinical Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2018, 4, 744.	3.4	0
309	WaldenstrÃ¶m Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematology/Oncology Clinics of North America, 2018, 32, xiii-xiv.	0.9	0
310	WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0
311	Waldenstromâ€™s Macroglobulinemia. , 2018, , 617-638.		0
312	A Novel Murine Model for Human Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 3646-3646.	0.6	0
313	Induction of Multiple Myeloma-Specific Cytotoxic T Lymphocytes Using HLA-A2.1-Specific CD19 and CD20 Peptides.. Blood, 2004, 104, 2477-2477.	0.6	0
314	Mutator Genes UDG and AID Appear To Be Normal in Class-Switch Deficient and Clonally Homogeneous Waldenstromâ€™s Macroglobulinemias Having Either Germline or Hypermutated Clonotypic IgH VDJ.. Blood, 2004, 104, 1359-1359.	0.6	0
315	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques.. Blood, 2005, 106, 504-504.	0.6	0
316	Hepatitis C Viral Infection Is Not Associated with Waldenstromâ€™s Macroglobulinemia.. Blood, 2005, 106, 4693-4693.	0.6	0
317	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. Blood, 2005, 106, 5150-5150.	0.6	0
318	Molecular Characterization of Clonotypic VDJ Sequences in Waldenstromâ€™s Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclonal B Cells.. Blood, 2006, 108, 4624-4624.	0.6	0
319	Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 2512-2512.	0.6	0
320	Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway.. Blood, 2010, 116, 1569-1569.	0.6	0
321	Involvement of Lipogenic Pathway In 5-Azacytidine-Induced Cytotoxicity In Waldenstrom's Macroglobulinemia. Blood, 2010, 116, 2991-2991.	0.6	0
322	Targeting Sp1 Transactivation In Waldenstrom's Macroglobulinemia: a Novel Therapeutic Option. Blood, 2010, 116, 120-120.	0.6	0
323	Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia. Blood, 2010, 116, 4159-4159.	0.6	0
324	Aberrant Expression of Oct-2, Spi-B, and Id2/Id1 Is Associated with Repression of Plasma Cell Differentiation in WaldenstroÌˆm's Macroglobulinemia. Blood, 2011, 118, 86-86.	0.6	0

#	Article	IF	Citations
325	The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia. Blood, 2011, 118, 2713-2713.	0.6	0
326	MicroRNA-21 and â^'155 Are Induced by a Widely Expressed Mutation in MyD88 (L265P) in Waldenstrom's Macroglobulinemia,. Blood, 2011, 118, 3957-3957.	0.6	0
327	Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of WaldenstroÌˆm Macroglobulinemia. Blood, 2012, 120, 3723-3723.	0.6	0
328	WaldenstrÃ¶mâ€™s Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2013, , 83-109.		0
329	WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2014, , 303-329.		0
330	Bing-Neel Syndrome: A Rare Complication of Waldenstromâ€™s Macroglobulinemia. Blood, 2014, 124, 5480-5480.	0.6	0
331	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	0.6	0
332	Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies. Blood, 2018, 132, 263-263.	0.6	0
333	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 207-227.		0